Nephrotoxicity: Imatinib is associated with a decline in renal function; may be associated with duration of therapy 肾毒性:伊马替尼与肾功能下降有关;可能与治疗持续时间有关。 DOSING | 剂量: Children and Adolescents: Oral: 340 mg/m2 /day administered once daily; maximum daily dose: 600 mg/day....
improved during treatment with imatinib. The median duration ofPFSwas 9.2months, and medianoverall survival(OS) was 34months. While the median PFS seems clinically favorable compared to other reports of metastatic chordoma patients, the indolent nature of the disease and the lack of documented tumor...
Indicated following complete gross resection of kit (CD117)-positive GIST 400 mg PO once daily Optimal treatment duration is unknown; may continue for 3-years based on a clinical trial Dosage Modifications Hematologic toxicity Starting dose 100 mg/day ie, ASM associated eosinophilia and HES/CEL wi...
We evaluated hypogammaglobulinemia as a potential 'off-target' action of imatinib in children with CML. A cross-sectional, observational study was performed. Patients with CML in chronic phase, age <18-years at diagnosis, receiving imatinib for a duration exceeding 6-months were enrolled. Serum...
patients following complete gross resection of GIST. In clinical trials, one year of Gleevec and three years of Gleevec were studied. In the patient population defined in Study 2, three years of Gleevec is recommended [seeClinical Studies]. The optimal treatment duration with Gleevec is not ...
Resistance to ATP-competitive kinase inhibitors limits the duration of response that can be achieved with this class of therapeutics. Thus, it is urgent to Acta Pharmacologica Sinica www.chinaphar.com Wu LX et al npg 407 Figure 4. C817 triggers mitochondrial pathway of apoptosis in imatinib-...
Longest treatment duration was 17 weeks (median 6). Conclusion: Panobinostat and IM can be administered at doses achieving target inhibition in vivo. Further clinical exploration of patients with treatment-refractory GIST is warranted. Correlative studies in this trial may help to optimise dosing ...
In patients with accelerated-phase CML (median treatment duration of 11 months), imatinib mesylate 600 mg/day (n = 119) was effective as shown by the proportion of patients with responses (MCR 28%, CCR 19%, hematologic response [HR] 71%); the estimated 12-month progression-free and overa...
Aims of the study The purpose of this phase 2 study was to determine the safety and tolerability of a combination of imatinib mesylate and cytarabine. Other end points were rate of complete hematologic response (CHR) at 6 months, rates and duration of major cytogenetic response (MCR) and comp...
patients following complete gross resection of GIST. In clinical trials, one year of Gleevec and three years of Gleevec were studied. In the patient population defined in Study 2, three years of Gleevec is recommended [seeClinical Studies]. The optimal treatment duration with Gleevec is not ...